Mediastinal Lymph Node Dissection in Resected Lung Cancer: Morbidity and Accuracy of Staging
|
|
- Betty Eaton
- 6 years ago
- Views:
Transcription
1 Mediastinal Lymph Node Dissection in Resected Lung Cancer: Morbidity and Accuracy of Staging Ewald C. M. Bollen, MD, Cees J. van Duin, MD, Paul H. M. H. Theunissen, MD, PhD, Bep E. v. t Hof-Grootenboer, BSc, and Geert H. Blijham, MD, PhD Departments of Surgery and Pathology, De Wever Hospital, Heerlen; Department of Pathology, University of Nijmegen; and Department of Oncology, University Hospital Utrecht, the Netherlands A study was performed to investigate the morbidity of mediastinal lymph node dissection (MND) and to establish its contribution to the accuracy of staging in surgically treated non-small cell lung cancer. Between 1988 and the middle of 1991 a systematic sampling of mediastinal lymph nodes was done in 20 patients and a MND was carried out in 65 patients. Data from these patients were compared with those from a control group of 70 patients operated on in 1986 and 1987, who would have had MND if they had been treated in the years after The groups were comparable according to important clinical characteristics. There was a significantly greater fluid production via the drains in the groups with systematic sampling and MND, compared with the controls. Volume of blood lost during the operation and number of units blood transfused perioperatively were not significantly different between the groups. Three lesions of the recurrent laryngeal nerve and two episodes of chylothorax were observed, all probably caused by MND. The discovery ratio for N2 disease in the MND and systematic sampling groups together compared with the control group was 2.1, with a 9 confidence interval from 1.04 to 4.2. (~nn rhorac surg z993;55:96z-a peration still offers the best prospects for patients 0 with non-small cell lung cancer. This certainly applies to the early stages of the disease. There is still controversy regarding the role of operation when the mediastinal lymph nodes (N2) are affected. In retrospective studies, a prognosis of 19% to 30% actuarial 5-year survival in N2 disease [14] has been claimed. Other writers doubt the general usefulness of operation in N2 disease, restricting it to patients whose nodal metastases escape the preoperative evaluation [5-7]. Once operation is indicated in N2 disease, it is generally agreed that mediastinal node dissection (MND) has to be performed, first, because all tumor has to be excised, and, second, because MND has been claimed to lead to a more accurate staging [8]. To what extent MND improves the accuracy of staging has not fully been studied. It is remarkable, for a procedure so generally recommended [9], that so few data are available with regard to its morbidity. In this study with historical controls, a comparison is made between plain resection and resection with exploration of the mediastinal nodes to determine whether, and to what extent, MND improves accuracy of staging, and to determine the morbidity of MND. Material and Methods Study Period The study period ran from 1986 to the middle of During this period, 210 patients with non-small cell lung Accepted for publication July 30, Address reprint requests to Dr Bollen, Department of Surgery, De Wever Hospital, PO Box 4446, 6401 CX Heerlen, the Netherlands. cancer, 190 men and 20 women, were operated on in De Wever Hospital, Heerlen. The mean age was 63 years, ranging from 33 to 80 years. A squamous cell carcinoma was diagnosed 142 times (67.6%), an adenocarcinoma 44 times (21%), a large cell carcinoma 15 times, and another non-small cell lung cancer 9 times (4.3%). Pulmonary resection consisted of pneumonectomy in 64 patients (30.), lobectomy in 102 patients (48.6%), sleeve lobectomy in 17 patients (8.1%), segmentectomy or wedge resection in 14 patients (6.6%), and exploratory thoracotomy in 13 patients (6.2%). One hundred fifteen patients (54.8%) proved to be in stage I, 23 (11%) in stage 11, 62 (29.) in stage IIIa, and 10 (4.7%) in stage 11%. Patient Population The patient population was divided into three consecutive cohorts: in 1987 and early 1988 patients with non-small cell lung cancer underwent pulmonary resection without special attention to the mediastinal nodes; in 1988 an exploration of the mediastinum was added to the resection enabling systematic sampling (SS) of all the mediastinal node stations. Since 1989, instead of the sampling, MND became the routine procedure. The experimental group consisted of the patients with an SS (n = 20) or an MND (n = 65) operated on after In the same period, 26 other patients had no extended exploration of the mediastinum for various reasons: poor pulmonary or physical condition, severe silicosis (40% of the patients were former coal miners), much blood loss during the operation, age greater than 76 years, palliative resection, and exploratory thoracotomy (n = 7). The control group (n = 70) consisted of those patients operated on in 1986 and 1987 who would have been by The Society of Thoracic Surgeons /93/$6.00
2 962 BOLLEN ET AL Ann Thorac Surg 1993;55:961-6 selected for an exploration if they had been operated on after The same reasons for omitting mediastinal exploration in patients operated on after 1988 also applied to those operated on in 1986 and Thus, 29 patients had to be excluded from the control group. In summary, of the 210 patients operated on in the study period, 155 could finally be included in the case control study. Pretreatment In all patients a computed tomographic scan was part of the pretreatment staging. Until 1989 a mediastinoscopy was done only when nodes larger than 1.0 cm in diameter were seen on the computed tomographic scan. Since 1989 cervical mediastinoscopy has been performed routinely. Preoperative parasternal mediastinal exploration for left upper lobe tumors was performed in 6 patients of the control group and in 1 patient of the MND group. Patients with positive nodes found at preoperative mediastinal examination were excluded from resectional therapy. In the study period, 40 patients were excluded for operation because of positive findings at cervical mediastinoscopy. Positive findings at parasternal mediastinoscopy never excluded patients for operation. Mediastinal Node Dissection Technique Mediastinal node dissection was performed according to the method described by Naruke, Martini, and their associates [2, 101. In case of a pneumonectomy or upper lobe resection, mediastinal nodes were dissected en bloc. On the right side this applied to nodes in the superior or paratracheal compartments, and on the left side this applied to nodes in the aortopulmonary window. The nodes in the supraaortic compartment on the left side were merely sampled rather than dissected free. In the case of a lower lobe resection, the above-mentioned procedure was done separately. In all resections excision of the nodes in the subcarinal and inferior mediastinum was done after resection of the tumor. The nodes were numbered according to the chart of Naruke and coworkers [ll]. They were examined histologically and classified as NO, N1, or N2 according to the TNM system [=I. In the control group, only palpable lymph nodes suspected of being malignant were sampled before or after resection. One drain was left in situ for 24 hours after a pneumonectomy. After every other resection two drains were left in situ, one in the sinus pleura and the other one in the upper thorax. The fluid production via the drains and the time that the drains remained in situ were only measured in patients who had not undergone pneumonectomy. Accuracy of Staging To determine the accuracy of N staging, the number of N2 diseases discovered through exploration of the mediastinum was compared with the number discovered when no exploration was done. The relative discovery probability or discovery ratio was calculated by analogy with the calculation of the relative risk ratio [13]. The confidence interval was also determined. Statistics The data from the patients were processed by SFSS (Statistical Package for Social Studies). The three groups (MND, SS, and control) were compared using the 2 test for nominal data and one-way analysis of variance or the Kruskal-Wallis test for metric data, depending on the distribution (normal or outliers). The 9 confidence intervals for the discovery ratio were calculated using the large-sample approximation as is usually done for relative risks. Results Patient Characteristics Relevant characteristics of the 155 patients studied are summarized in Table 1. No significant differences were found between the three groups (MND, SS, and control) for age, sex, coughing, dyspnea, hemoptysis, number of asymptomatic patients, weight loss 6 months before operation, albumin level, lactate dehydrogenase level, lung function (mean forced expiratory volume in 1 second, vital capacity, and diffusing capacity), type of resection, histology, and T stage of the tumor. Morbidity PERIOPERATIVE BLOOD LOSS. Three parameters for blood loss during and after the operation were studied: the amount of blood lost during the operation itself, blood loss after operation making repeat thoracotomy necessary, and the need for blood transfusions during and after the operation within the period of hospital admission. Results are summarized in Table 2. Although some differences in the investigated parameters were observed, none of these were significant. In the 4 patients who needed a repeat thoracotomy, this procedure was not related to the mediastinal exploration. Of the total of 155 patients, 54% received no blood transfusion during the hospital admission. FLUID PRODUCTION VIA THE DRAINS. There was a significantly higher fluid production in the MND and SS groups compared with that in the control groups (Table 3). This applies to the production during the first 2 days as well as to the total production. The higher drain production in the MND and SS patients was not related to the number of days in which the drains remained in situ. BRONCHOPLEURAL FISTULA. Fistulas were seen three times (Table 4). Two fistulas developed within 10 days of pneumonectomy, one in the control group and one in the SS group. These fistulas were closed surgically with an uneventful postoperative course. A bronchopleural fistula with empyema developed in 1 patient in the SS group after pneumonectomy with rib resections (T3 Nl). The condition of the patient was poor, and he died 3 months after the pneumonectomy. No fistula developed in the MND group. HOARSENESS. Two patients in the control group and 6 patients in the MND group had hoarseness (see Table 4).
3 Ann Thorac Surg 1993;55:%1-6 BOLLEN ET AL 963 Table I. Characteristics of the Three Groups MND SS Control Variable (n = 65) (n = 20) (n = 70) Demographic features Age (Y) Male Clinical features Coughing preop Dyspnea preop Hemoptysis preop Asymptomatic Weight loss > Biochemistry Albumin (gl) LDH (UL) Lung function tests FEV, (% predicted) Vital capacity (% predicted) Diffusion capacity (%) Thoracotomy side Left Right Resection performed Pneumonectomy Lobectomy Sleeve lobectomy Lesser resection Histology Squamous cell caranoma Adenocarcinoma Giant cell carcinoma Other histology Tumor staging T1 T2 T3 64 (8) 8 72% 43% 32% 22% 21 % 33.4 (4.8) 382 (124) 82 (18) 94 (15) 72 (16) % 46% 9% 3% 64% 24% 3% 9% 34% 53% 13% 63 (10) 9 80% 53% 3 30% (3.0) 325 (68) 73 (15) 93 (14) 78 (21) % 4 10% % 63% 64 (9) 94% 66% 41% 24% 34% 16% 34.2 (3.8) 348 (94) 76 (22) 92 (18) 74 (16) % 53% 10% 7% 67% 23% 7% 3% 44% 50% 6% a Where applicable, values are shown as mean (standard deviation). No significant differences were found using one-way analysis of variance or J tests. FEV, = forced expiratory volume in 1 second; LDH = lactate dehydrogenase; MND = mediastinal lymph node dissection; SS = systematic sampling. Both patients in the control group underwent a left pneumonectomy. The recurrent laryngeal nerve had to be cut to make an adequate dissection of the N2 nodes in the Table 2. Blood Loss Variable MND SS Control avalue Bleeding with repeat thoracotomy NS (No.) Median operative blood loss (ml) NS Mean blood transfusions within NS admission period (ml) By Kruskal-Wallis test or one-way analysis of variance MND = mediastinal lymph node dissection; NS = not significant; SS = systematic sampling. Table 3. Fluid Production Via Drains Day MND ss Control p Valueb NS NS Total 1,050 1, <0.001 Values are shown as median in milliliters. MND = mediastinal lymph node dissection; SS = systematic sampling. By Kruskal-Wallis test. NS = not significant; aortopulmonary window possible. For the same reason, the nerve was cut in 3 patients in the MND group. In 3 other patients in this group, left pneumonectomy, left lobectomy, and right lower lobectomy were performed but the nerve was damaged unintentionally. In these patients the hoarseness must be regarded as a complication of the MND. CHYLOTHORAX. Chylothorax developed in 2 patients in the MND group who underwent left lower lobectomy and right upper lobectomy, respectively (see Table 4). Both patients were treated conservatively with an uneventful course. Other complications encountered OTHER COMPLICATIONS. were subcutaneous emphysema (2), air leakage longer than 2 weeks (5), pneumonia (5), atelectasis (4), septicemia (2), thrombosis (l), paresis of the peroneal nerve (l), and cardiac complication (4)(see Table 4). No wound infection or other disturbances in wound healing were found. All these complications were proportionally dis- Table 4. Morbidity and Mortality MND ss Control Complication (n = 65) (n = 20) (n = 70) Bronchopleural fistula Without empyema With empyema Recurrent nerve lesion Intentional Unintentional Chylothorax Subcutaneous emphysema Air leakage > 2 wk Pneumonia Atelectasis Septicemia Thrombosis Paresis of peroneal nerve Wound infection Cardiac complication Death h4nd = mediastinal lymph node dissection; Ph3 SS = systematic sam-
4 964 BOLLEN ET AL Ann Thorac Surg 1993:55:%14 Table 5. N2 Positive Node Stations and Total Node Stations Sampled bv Station in Each Grouv Node 1 2R 2L 3A 38 4R 4L Total Station Superior mediastinal Right upper paratracheal Left upper paratracheal Low pretracheal Low retrotracheal Right tracheobronchial Left tracheobronchial Subaortic Paraaortic Subcarinal Paraesophageal Pulmonary ligament MND (n = 65) ss (n = 20) Control (n = 70) a Data are shown as number of positive node stations, with number of node stations sampled or removed in parentheses. MND = mediastinal lymph node dissection; SS = systematic sampling. tributed over the MND, SS, and control groups. There was no significant difference among the three groups with respect to time to discharge from hospital. Mortality The mortality rate (within 30 days postoperatively) for all 210 patients was 5.2%. The mortality rate for pneumonectomy was 9.4%, for lobectomy 3.8%, and for thoracotomy without resection 7.6%. There were no deaths after sleeve resection, segrnentectomy, or wedge resection. Of the 155 patients studied, 7 patients died within 30 days postoperatively; 3 patients were in the MND group, 1 in the SS group, and 3 in the control group (see Table 4). No death could be related to MND. Accuracy of S tuging Three hundred fifty-one node stations were dissected in the MND group, 97 node stations were sampled in the SS group, and 73 stations were sampled in the control group. The distribution over the different node stations in each group is given in Table 5. In the whole population of 210 patients 40 were classi- fied as having stage N2 disease. Eight patient& operated on before 1988 and 4 after-were in the exclusion gr0up:j. Sixteen of the remaining 32 patients with N2 disease were found in the MND group, 7 in the SS group, and 9 in the control group (Table 6). The discovery ratio of N2 disease for MND against the controls was 1.9 (9 confidence interval, 0.9 to 4.0); for SS against controls, 2.7 (9 confidence interval, 1.2 to 6.3); and for MND plus SS against controls, 2.1 (9 confidence interval, 1.04 to 4.2). The last two ratios are significantly different from 1 (2 tests). Calculations on the total number of observed N2 nodes emphasize these findings (see Table 6). Comment Mediastinal lymph node dissection has been claimed to improve both the accuracy of staging [8] and the survival of patients with N2 non-small cell lung cancers [1-4, 141, although this view is not universally held [15]. In some studies an extended mediastinal lymph node dissection, through a median stemotomy [16, 171, has even been Table 6. N2 Disease and N2 Positive Node Stations in the Three Groups MND ss MND + SS Control Variable (n = 65) (n = 20) (n = 85) (n = 70) N2 disease Number of patients Percent of patients Discovery ratio Confidence interval of discovery ratio N2 positive node stations Total Mean per N2 patient Mean per patient MND = mediastinal lymph node dissection; SS = systematic sampling.
5 Ann Thorac Surg 19!33:55:%1-6 BOLLEN ET AL 965 performed to remove lymph nodes from the contralateral side. Few data are available on the morbidity of the procedure or its contribution to the accuracy of staging. In this study, morbidity and accuracy of staging have been determined by systematically comparing three groups of patients who had plain resection, resection with sampling of the mediastinal lymph nodes, or resection with dissection of the nodes. Although the patients in the groups were not selected at random, we have four reasons for believing that comparing the groups is a methodologically valid procedure. First, the resectional strategy has not changed during the past 5 years. Second, all the operations were performed by two of us. Third, there were no changes during the study period except a more accurate preoperative staging by means of a routine mediastinoscopy and intraoperative exploration of the mediastinum. Finally, we selected those patients as controls who would have been eligible for SS or MND had they been seen in later years. The comparability of the three groups was substantiated by their matching in the most important clinical characteristics. The expected morbidity of MND includes extra blood loss [18], devascularization of the bronchus, and damage to some intrathoracic structures, especially the recurrent laryngeal nerve and the thoracic duct. In the present study, blood loss during the operation did not differ among the groups. The MND group had no higher rate of blood transfusion during or after the operation. However, the higher fluid production via the two drains indirectly indicates a somewhat higher perioperative blood loss. It is generally assumed that MND may lead to devascularization of the bronchus, increasing the risks of a fistula [19]. Because no fistulas were found in patients within the MND group this assumption is not confirmed. The lack of fistulas might be the result of the fact that the bronchial stump in the MND patients was covered with a vital pleural or pericardial flap. The most important complication associated with MND appears to be damage to the recurrent laryngeal nerve and the lymphatic vessels. In N2 disease, especially in left upper lobe cancer affecting the nodes in the aortopulmonary window, the recurrent laryngeal nerve may be cut intentionally to clear out this compartment adequately. However, if the N2 nodes in the aortopulmonary window have not been affected, recurrent nerve paralysis should be considered a serious side effect. Its occurrence, as in thyroid operations 1201, underlines the necessity of identifying the recurrent laryngeal nerve before continuing the dissection. Chylous fluid production is generally accepted as an adverse effect of lymph node dissection in cancer operations. In nonthoracic operations this complication is often treated conservatively [21], but in the case of chylothorax a more aggressive policy is followed [22]. Fortunately the 2 patients with chylothorax in this study, probably due to the MND, could be treated conservatively. To prevent this complication it might be important to ligate as much tissue as possible during the dissection. In inguinal lymphadenectomy fairly good results have been achieved by covering the operative field with a film of fibrin glue ~31. The overall mortality of 5.2% is within acceptable ranges [24] taking into account that in this region 40% of the male population has worked for more than 10 years in coal mines and that many patients consequently demonstrated extensive fibrotic changes with distortion of the lung and mediastinal structures. Most studies on the accuracy of staging have dealt with preoperative staging. In a recent study from the Bromptom Hospital [25], clinical TNM staging (determined by means of routine computed tomographic scans and selective mediastinoscopy) has been compared with pathological TNM or postsurgical staging. Mediastinal lymph node dissection has routinely been performed. The preoperative underestimation of 23. of the N stage in that study is in accordance with the 27.1% in our study (23 patients with N2 disease by SS or MND out of 85 with clinically less than N2 disease). The slightly higher percentage in the present study might be due to the fact that not all patients in the MND and SS groups underwent mediastinoscopy, and only a few patients underwent preoperative parasternal mediastinal exploration in case of a left upper lobe tumor. With respect to intraoperative accuracy of staging, the main issue in this context, it can be concluded that the discovery ratio suggests that twice as many patients with N2 disease are detected if a mediastinal lymph node exploration is performed. Perhaps the real difference in discovery ratio is even higher, as in our control group no routine mediastinoscopy was performed, whereas during the MND period a number of patients were excluded from resection because of positive nodes found during mediastinoscopy but not detected by the computed tomographic scan. Relatively more N2 diseases are identified by SS than by MND. Because the number of SS patients is very small, it is not possible to draw any conclusion in this respect. We even decided to change from SS to MND because MND seems to be more accurate than SS and as easy to perform. In addition, we expected from MND a therapeutic effect in N2 disease. In this study 351 node stations were totally removed in the MND group. This means an average of 5.85 stations per patient. In the SS group an average of 4.85 node stations per patient were sampled. Theoretically, on the right side with a complete mediastinal node dissection eight stations (1, ZR, 3A, 38, 4R, 7, 8, 9) can be removed and on the left side, 10 stations (1, 2L, 3A, 3B, 4L, 5, 6, 7, 8, 9). In our series, however, 3B has never been removed in left-sided tumors and only eight times in right-sided tumors. Besides, we only removed upper mediastinal node stations in left-sided tumors if there was any suspicion of abnormality. In some cases not all stations contained nodes or they were not adequately separated over the different stations. Even with these restrictions, the difference between number of stations actually sampled and those theoretically accessible is striking. This reflects the learning curve. Especially in the beginning of the study period sometimes we were not yet fully motivated
6 966 BOLLEN ET AL Ann Thorac Surg 1993;51-6 to remove node stations when they were already sampled by mediastinoscopy and revealed to be negative. It is our present practice to remove all stations in right-sided tumors except for stations 1 and 3B, which are seldom excised. For left-sided tumors, all stations are removed except for stations 1, 2L, 3A, and 3B. Mediastinal node dissection is now an obligatory part of resectional therapy. It is regarded as a safe procedure and provides a superior method for staging the mediastinal nodes. However, the fluid production from the drains suggests a higher blood loss in the MND group. Lesions of the recurrent laryngeal nerve are preventable. Supported in part by a grant from IKL, Comprehensive Cancer Centre Limburg, the Netherlands. We wish to express our appreciation to Dr Ben I. Davies for his valuable linguistic corrections and Dr Jan A. van Noord, Department of Respiratory Diseases, De Wever Hospital for critical reviewing of the manuscript. References 1. Martini N, Flehinger BJ, &man MB, Beattie EJ Jr. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 1983;198:3% Naruke T, Goya T, Tsuchiya R, Suemasu K. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 1988;46: Watanabe Y, Shimizu J, Oda M, et al. Aggressive surgical intervention in N2 non-small cell cancer of the lung. Ann Thorac Surg 1991;51:25=1. 4. Patterson GA, Piazza D, Pearson FG, et al. Significance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg 1987;43: Pearson FG, De Larue NC, Ilves R, Todd TR, Cooper JD. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982;83: Goldstraw P. The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer. Thorax 1992; Shields TW. The significance of ipsilateral lymph node metastasis (N2 disease) in non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1990;99:& Gaer JA, Goldstraw P. Intraoperative assessment of nodal staging at thoracotomy for carcinoma of the bronchus. Eur J Ci rdiothorac Surg 1990; Consensus report of the IASLC Working Party on Pretreatment Minimal Staging. Lung Cancer 1991; Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987; Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978; Mountain CF. A new international staging system for lung cancer. Chest 1986;892233S. 13. Moms JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J Clin Res 1988; Cahan WG. Radical lobectomy. J Thoracic Cardiovasc Surg 10;39: Yasumitsu T, In K, Nakagawa K, Kotake Y. Necessity of mediastinal lymph nodes dissection in operable lung cancer (a randomized study). Lung Cancer 1991;7(Suppl): Naruke T, Goya T, Tsuchiya R, Suemasu K. Extended radical oxration for N2 left lung cancer through median stemotomy. Lung Cancer 1988;4(SuppI):A hata E, Miyamoto H, Mitoma Y, Hayakawa K. Systematic bllateral mediastinal dissection and en bloc pulmonary resection through the median stemotomy. Lung Cancer 1991; 7:Suppl): Vogt-Moykopf I, Branscheid D, Bulzebruck H, Probst G. Pktuelle Aspekte der neuen Stadieneinteilung beim Bronchialcarcinom und ihre kliruschen Konsequenzen. Der Chirurg 1989;60: 16-23, 19. Wilkens EW Jr. Bronchopleural fistula: prophylaxis. In: Grill0 HC, Eschapasse H, eds. International trends in general tnoracic surgery, vol2. Major challenges. Philadelphia: Sauncers, Mountain JC, Colcock BP. The recurrent laryngeal nerve in thyroid operations. Surg Gynecol Obstet 1971;133: Femgni RG, Novicki DE. Chylous asates complicating genitourinary oncological surgery. J Urol 1985;134377& Shirai T, Amano J, Takabe K. Thoracoscopic diagnosis and treatment of chylothorax after pneumonectomy. Ann Thorac Surg 1991;52:30& llouchot 0, Bouchot-Hermouet FB, Karam G, Glemain P, Pannier M, Auvigne J. Prevention des complications de la lymphad6nectomie inguinale. J Urol (Paris) 1990;96: Ginsberg RJ, Hill LD, Eagan RT, et al. Modem thirty-day operative mortality for surgical resections in lung cancer. J horac Cardiovasc Surg 1983;86: emando HC, Goldstraw P. The accuracy of clinical evaluaive intrathoraac staging in lung cancer as assessed by postsurgical pathologic staging. Cancer 1990;65:
Lymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationImpact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer
Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationMediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*
Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi
More informationMediastinal Lymph Node Dissection Improves Survival in Patients With Stages II and IIIa Non- Small Cell Lung Cancer
J. MAXWELL CHAMBERLAIN MEMORIAL PAPER Mediastinal Lymph Node Dissection Improves Survival in Patients With Stages II and IIIa Non- Small Cell Lung Cancer Steven M. Keller, MD, Sudeshna Adak, PhD, Henry
More informationIn non small cell lung cancer, metastasis to lymph nodes, the N factor, is
Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,
More informationSignificance of Metastatic Disease
Significance of Metastatic Disease in Subaortic Lymph Nodes G. A. Patterson, M.D., D. Piazza, M.D., F. G. Pearson, M.D., T. R. J. Todd, M.D., R. J. Ginsberg, M.D., M. Goldberg, M.D., P. Waters, M.D., D.
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationS promise of long-term survival for patients with nonsmall
Aggressive Surgical ntervention in N Non-Small Cell Cancer of the Lung Yoh Watanabe, MD, Junzo Shimizu, MD, Makoto Oda, MD, Yoshinobu Hayashi, MD, Shinichiro Watanabe, MD, Yasuhiko Tatsuzawa, MD, Takashi
More informationVideo-Mediastinoscopy Thoracoscopy (VATS)
Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566
More informationPrognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer
Jpn. J. Clin. Oncol. 198, 1 (), 7-1 Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer KEIICHI SUEMASU, M.D. AND TSUGUO NARUKE, M.D. Department of Surgery,
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationRoutine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF)
Routine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF) Abstract The results of 25 cases underwent a pedicled pericardial flap coverage for the bronchial
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationComparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Junhua Zhang*,
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More informationThe Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma
The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D.,
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationState of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter?
Review Article State of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter? Laura Romero Vielva 1, Manuel Wong Jaen 1, José A. Maestre Alcácer 2, Mecedes Canela Cardona
More informationSite of Recurrence in Patients. of the Lung Resected for Cure. with Stages I and I1 Carcinoma
Site of Recurrence in Patients with Stages I and I1 Carcinoma of the Lung Resected for Cure Steven C. Immerman, M.D., Robert M. Vanecko, M.D., Willard A. Fry, M.D., Louis R. Head, M.D., and Thomas W. Shields,
More informationShort- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer
Original Article Short- and Long-Term Outcomes after Pneumonectomy for Primary Lung Cancer Takeshi Kawaguchi, MD, Takashi Tojo, MD, Keiji Kushibe, MD, Michitaka Kimura, MD, Yoko Nagata, MD, and Shigeki
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/21364
More informationLymph Node MetastasG Tsuguo Naruke, M.D., Tomoyuki Goya, M.D., Ryosuke Tsuchiya, M.D., and Keiichi Suemasu, M.D.
ORIGINAL ARTICLES The Importance of Surgery to Non-Small Cell Carcinoma of Lung with Mediastinal Lymph Node MetastasG Tsuguo Naruke, M.D., Tomoyuki Goya, M.D., Ryosuke Tsuchiya, M.D., and Keiichi Suemasu,
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationThe Role of Radiation Therapy
The Role of Radiation Therapy and Surgery in the Treatment of Bronchogenic Carcinoma R Adams Cowley, M.D., Morris J. Wizenberg, M.D., and Eugene J. Linberg, M.D. A study of the combined use of preoperative
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationCarcinoma of the Lung in Women
Carcinoma of the Lung in Marvin M. Kirsh, M.D., Jeanne Tashian, M.A., and Herbert Sloan, M.D. ABSTRACT The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph
More informationEXTENDED SLEEVE LOBECTOMY FOR LUNG CANCER: THE AVOIDANCE OF PNEUMONECTOMY
EXTENDED SLEEVE LOBECTOMY FOR LUNG CANCER: THE AVOIDANCE OF PNEUMONECTOMY Morihito Okada, MD Noriaki Tsubota, MD Masahiro Yoshimura, MD Yoshifumi Miyamoto, MD Hidehito Matsuoka, MD, Shinsuke Satake, MD
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationBronchial Carcinoma and the Lymphatic Sump: The Importance of Bronchoscopic Findings
Bronchial Carcinoma and the Lymphatic Sump: The Importance of Bronchoscopic Findings Gordon F. Murray, M.D., Ormond C. Mendes, M.D., and Benson R. Wilcox, M.D. ABSTRACT The lymphatic sump of Borrie is
More informationNon small cell lung cancer (NSCLC) with ipsilateral mediastinal
Results of surgical intervention for p-stage IIIA (N2) non small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationCompletion pneumonectomy for lung cancer
Journal of BUON 7: 235-240, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Completion pneumonectomy for lung cancer N. Baltayiannis, D. Anagnostopoulos, N. Bolanos, L. Tsourelis
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationThe Significance of One-Station N2 Disease in the Prognosis of Patients With Nonsmall-Cell Lung Cancer
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationLymph node metastasis is one of the most important prognostic
ORIGINAL ARTICLE Comparison of Survival and Recurrence Pattern Between Two-Field and Three-Field Lymph Node Dissections for Upper Thoracic Esophageal Squamous Cell Carcinoma Young Mog Shim, MD, Hong Kwan
More informationProper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer
Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,
More informationD tion therapy, complete resection of a tumor offers
Determinants of Perioperative Morbidity and Mortality After Pneumonectomy Rakesh Wahi, MBBS, Marion J. McMurtrey, MD, Louis F. DeCaro, MD, Clifton F. Mountain, MD, Mohamed K. Ali, MD, Terry L. Smith, MS,
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationQuality of Life (QOL) versus Curability for Lung Cancer Surgery
Quality of Life (QOL) versus Curability for Lung Cancer Surgery Hirokuni Yoshimura, MD Standard operations for lung cancer patients are generally accepted as performing lobectomy or pneumonectomy on the
More informationPrognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer
Prognostic Significance of Metastasis to the Highest Mediastinal Lymph Node in Nonsmall Cell Lung Cancer Yukinori Sakao, MD, PhD, Hideaki Miyamoto, MD, PhD, Akio Yamazaki, MD, PhD, Tsumin Oh, MD, Ryuta
More informationSurgical resection is the first treatment of choice for
Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationDespite their reputation of benignity, carcinoid tumors
Operative Risk and Prognostic Factors of Typical Bronchial Carcinoid Tumors Xavier Ducrocq, MD, Pascal Thomas, MD, Gilbert Massard, MD, Pierre Barsotti, MD, Roger Giudicelli, MD, Pierre Fuentes, MD, and
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationSurgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease)
Eur J Cardio-thorac Surg (1996) 10:649-655 Springer-Verlag 1996 P. De Leyn P. Schoonooghe G. Deneffe D. Van Raemdonck W. Coosemans J. Vansteenkiste T. Lerut Surgery for non-small cell lung cancer with
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationOmission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures
Review Omission of Mediastinal Lymph Node Dissection in Lung Cancer: Its Techniques and Diagnostic Procedures Hiroaki Nomori, MD, PhD, Kazunori Iwatani, MD, Hironori Kobayashi, MD, Atsushi Mori, MD, and
More informationSkip Metastasis to the Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer
Skip Metastasis to the Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer Ichiro Yoshino, MD, Hideki Yokoyama, MD, Tokujiro Yano, MD, Takashi Ueda, MD, Eiji Takai, MD, Kazuki Mizutani, MD, Hiroshi Asoh,
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationPredictive risk factors for lymph node metastasis in patients with resected nonsmall cell lung cancer: a case control study
Moulla et al. Journal of Cardiothoracic Surgery (2019) 14:11 https://doi.org/10.1186/s13019-019-0831-0 RESEARCH ARTICLE Open Access Predictive risk factors for lymph node metastasis in patients with resected
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationGUIDELINES FOR CANCER IMAGING Lung Cancer
GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for
More informationMedian Sternotomy for Pneumonectomy in Patients With Pulmonary Complications of Tuberculosis
Median Sternotomy for Pneumonectomy in Patients With Pulmonary Complications of Tuberculosis Cliff P. Connery, MD, James Knoetgen III, MD, Constantine E. Anagnostopoulos, MD, and Madeline V. Svitak, BS,
More informationIncidence of local recurrence and second primary tumors in resected stage I lung cancer
Incidence of local recurrence and second primary tumors in resected stage I lung cancer From 1973 to 1985, 598 patients underwent resection for stage I non-small-cell lung cancer. There were 291 T1 lesions
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationIntraoperative Radioisotope Sentinel Lymph Node Mapping in Non Small Cell Lung Cancer
Intraoperative Radioisotope Sentinel Lymph Node Mapping in Non Small Cell Lung Cancer Michael J. Liptay, MD, Gregory A. Masters, MD, David J. Winchester, MD, Brian L. Edelman, MD, Ben J. Garrido, BA, Todd
More informationPatients with pathologically diagnosed involved mediastinal
MINI-SYMPOSIUM ON EMERGING TECHNIQUES FOR LUNG CANCER STAGING European Trends in Preoperative and Intraoperative Nodal Staging: ESTS Guidelines P. De Leyn, MF, PhD,* D. Lardinois, MD, P. Van Schil, MD,
More informationA carcinoma of the lung reported by Graham and. Predicted Pulmonary Function and Survival After Pneumonectomy for Primary Lung Carcinoma
Predicted Pulmonary Function and Survival After Pneumonectomy for Primary Lung Carcinoma Joe B. Putnam, Jr, MD, David E. Lammermeier, MD, Rolando Colon, MD, Marion J. McMurtrey, MD, Mohammed K. Ali, MD,
More informationCurrent Management of Postpneumonectomy Bronchopleural Fistula
Current Management of Postpneumonectomy Bronchopleural Fistula Shaf Keshavjee MD MSc FRCSC FACS Surgeon-in-Chief, University Health Network James Wallace McCutcheon Chair in Surgery Professor, Division
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationAJCC-NCRA Education Needs Assessment Results
AJCC-NCRA Education Needs Assessment Results Donna M. Gress, RHIT, CTR Survey Tool 1 Survey Development, Delivery, Analysis THANKS to NCRA for the following work Developed survey with input from partners
More informationThe 8th Edition Lung Cancer Stage Classification
The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationLong-Term Survival After Video-Assisted Thoracic Surgery Lobectomy for Primary Lung Cancer
Long-Term Survival After Video-Assisted Thoracic Surgery Lobectomy for Primary Lung Cancer Kazumichi Yamamoto, MD, Akihiro Ohsumi, MD, Fumitsugu Kojima, MD, Naoko Imanishi, MD, Katsunari Matsuoka, MD,
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationPulmonary metastasectomy in uterine malignancies: outcome and prognostic factors
Original Article Pulmonary metastasectomy in uterine malignancies: outcome and prognostic factors Marco Anile, Sara Mantovani, Ylenia Pecoraro, Carolina Carillo, Lorenzo Gherzi, Andreina Pagini, Erino
More informationIn 1978, Cooper and associates first described resecting
Median Sternotomy Versus Thoracotomy to Resect Primary Lung Cancer: Analysis of 815 Cases James W. Asaph, MD, John R. Handy, Jr, MD, Gary L. Grunkemeier, PhD, E. Charles Douville, MD, Andrew C. Tsen, MD,
More informationTherapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer
Original Article Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer Hiroaki Kuroda 1,2, Yukinori Sakao 1,2, Mingyon Mun 2, Noriko Motoi 3, Yuichi Ishikawa 3, Ken
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationLong-term respiratory function recovery in patients with stage I lung cancer receiving video-assisted thoracic surgery versus thoracotomy
Original Article Long-term respiratory function recovery in patients with stage I lung cancer receiving video-assisted thoracic surgery versus thoracotomy Tae Yun Park 1,2, Young Sik Park 2 1 Division
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationLung Cancer-a primer. Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo
Lung Cancer-a primer Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo CLINICAL CATEGORIES THE SOLITARY PULMONARY NODULE MULTIPLE PULMONARY NODULES Differential Diagnosis Malignant
More informationThe currently used standard cervical mediastinoscopy (SCM)
ORIGINAL ARTICLE The Role of Extended Cervical Mediastinoscopy in Staging of Non-small Cell Lung Cancer of the Left Lung and a Comparison with Integrated Positron Emission Tomography and Computed Tomography
More informationDifference of Sentinel Lymph Node Identification Between Tin Colloid and Phytate in Patients With Non Small Cell Lung Cancer
of Sentinel Lymph Node Identification Between Tin Colloid and Phytate in Patients With Non Small Cell Lung Cancer Hiroaki Nomori, MD, PhD, Yasuomi Ohba, MD, Kentaro Yoshimoto, MD, Hidekatsu Shibata, MD,
More information